

The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Item	Strength	NDC's	Pack	Description
L200183, Expiry: January 2024		68180-904-71	1 Blister of 28 tablets each	Each blister contains 28 film-coated tablets in the following order:
L201560, Expiry: September 2024	3mg/0.03 mg/0.451 mg & 0.451mg	68180-904-73	3 Blister of 28 tablets each	21 orange, round shaped, biconvex film-coated tablets debossed with "LU" on one side and "J63" on other side each containing 3 mg Drospirenone, 0.03 mg ethinyl estradiol and 0.451 mg Levomefolate calcium. 7 light orange, round shaped, biconvex film-coated tablets debossed with "LU" on one side and "J62" on other side each containing 0.451 mg Levomefolate calcium.

Lupin Pharmaceuticals, Inc. is initiating a recall of **Tydemy**™ (Drospirenone, Ethinyl Estradiol & Levomefolate Calcium Tablets 3/0.03/0.451mg & 0.451mg) to the **consumer** level. These lots are being recalled due to an out of specification ("OOS") result observed in inactive content (ascorbic acid) and impurity test at 12-month stability study specifically for lot (L200183). The recalled lots were distributed between June 03,2022 to May 31, 2023 to wholesalers and distributors nationwide.